Roche And Shionogi Aim For EU Accelerated Assessment
Executive Summary
Roche will learn this week if two potential anticancers it is developing - polatuzumab vedotin and entrectinib - will be okayed for fast track regulatory review when they are filed in the EU.
You may also be interested in...
EU Accelerated Assessment Tracker: Nine Definites So Far From 24 Requests In 2018
In 2018, the European Medicines Agency considered 24 requests from drug companies for fast-track review of their planned marketing authorization applications. The agency has granted at least nine requests, eleven have been rejected and the results of four have yet to be disclosed.
Roche Secures EU Fast-Track Review For Anticancers
The European Medicines Agency has okayed applications from Roche for EU accelerated review of two oncology drugs in late-stage development at the company.
EMA Says Yes To First Sickle Cell Drug For PRIME
Investigational drugs for sickle cell disease and diffuse large B cell lymphoma from Global Blood Therapeutics and Roche respectively have become the latest products to make it onto the European Medicines Agency’s PRIME scheme for speeding the development of drugs for unmet medical need.